Drug Discovery for Kinetoplastid Diseases: Future Directions

Area of Science:

• Parasitology
• Tropical Medicine
• Drug Discovery

Background:

• Kinetoplastid parasites cause significant human diseases including leishmaniasis, Chagas disease, and human African trypanosomiasis (HAT).
• While progress has been made in treating leishmaniasis and HAT, with HAT incidence decreasing, there's a critical need for new therapies.
• No new chemical or biological entities for these diseases have been approved in over three decades.

Purpose of the Study:

• To summarize the current status and future directions in drug discovery for kinetoplastid diseases.
• To highlight the need for novel therapeutic strategies for neglected tropical diseases.
• To discuss opportunities for accelerated progress based on recent scientific advancements.

Main Methods:

• The content is based on discussions from a gathering of scientists and physicians.
• It synthesizes current knowledge and expert opinions on kinetoplastid disease drug discovery.
• No specific experimental methods are detailed, as it's a review and discussion summary.

Main Results:

• Despite past successes, there's an urgent unmet need for new drugs against kinetoplastid parasites.
• Existing treatments are insufficient for Chagas disease and leishmaniasis.
• Recent advances in drug discovery tools and understanding host-parasite interactions present new opportunities.

Conclusions:

• Continued research and collaboration are essential for developing safe and effective treatments for kinetoplastid diseases.
• Accelerated progress in drug discovery is possible through novel insights and advanced tools.
• The prospect of eliminating some kinetoplastid diseases, like HAT, necessitates sustained efforts in treatment and prevention.